Welcome to our dedicated page for Cytosorbents news (Ticker: CTSO), a resource for investors and traders seeking the latest updates and insights on Cytosorbents stock.
CytoSorbents Corporation (NASDAQ: CTSO) generates frequent news flow around its blood purification technologies for intensive care and cardiac surgery. Company updates often center on clinical data, regulatory milestones, and commercial progress for its lead product CytoSorb® and its investigational DrugSorb™-ATR antithrombotic removal system.
Investors following CTSO news can expect announcements on quarterly and annual financial results, including revenue trends, gross margins, and cash flow initiatives, as seen in recent preliminary and reported results. Regulatory developments are another major theme, with detailed disclosures on the De Novo pathway for DrugSorb‑ATR, FDA appeal outcomes, pre‑submission meetings, and anticipated review timelines, as well as interactions with Health Canada.
CytoSorbents also issues news on scientific and medical events, such as presentations at major healthcare and cardiothoracic surgery conferences, company‑sponsored symposia, and global webinars on topics like sepsis and septic shock. These releases highlight new randomized trial results, real‑world evidence, and meta‑analyses involving CytoSorb and DrugSorb‑ATR, along with educational efforts aimed at clinicians in critical care and cardiac surgery.
Additional coverage includes participation in investor conferences, amendments to credit agreements, and workforce and cost reduction programs intended to influence the company’s financial trajectory. For readers tracking CTSO stock, the news stream provides insight into how CytoSorbents is advancing its blood purification platform, pursuing regulatory approvals, and expanding clinical adoption across high‑risk ICU and surgical indications. Bookmark this page to review the latest press releases, event notices, and business updates related to CytoSorbents.
CytoSorbents Corporation (NASDAQ: CTSO) will participate in the Cowen 41st Annual Health Care Conference on March 3, 2021. CEO Dr. Phillip Chan will provide insights into the company's advancements and future outlook, followed by a discussion with Dr. Joshua Jennings of Cowen. The company has made significant progress in critical care immunotherapy with its CytoSorb® blood purification technology, already utilized in over 121,000 human treatments. This technology is designed to treat severe inflammatory conditions and is approved in the EU, distributed across 67 countries.
CytoSorbents Corporation (NASDAQ: CTSO) announced a strong performance in 2020 with a preliminary revenue of $40.8 million, a 73% increase from 2019. The company aims for sales growth in 2021, focusing on U.S. FDA approval for CytoSorb to remove ticagrelor in cardiothoracic surgeries. The company plans to expand its manufacturing capacity and has already achieved FDA Emergency Use Authorization for CytoSorb in treating critically-ill COVID-19 patients. Upcoming earnings details will be disclosed on March 9, 2021.
CytoSorbents Corporation (NASDAQ: CTSO) has announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021. CEO Dr. Phillip Chan will engage in a fireside chat with Danielle Antalffy, highlighting the company's progress and future outlook. CytoSorbents specializes in critical care immunotherapy and its flagship product, CytoSorb®, is widely used for blood purification in critically ill patients. The technology is approved in the EU and has been utilized in over 121,000 treatments globally.
CytoSorbents Corporation (NASDAQ: CTSO) has received recognition from the UK's National Institute for Health and Care Excellence (NICE) regarding its CytoSorb blood purification technology. The Medtech Innovation Briefing highlights the ability of CytoSorb to reduce bleeding risks in cardiac surgery by eliminating the blood thinner ticagrelor. NICE's analysis indicates potential cost savings of £3,941 per procedure and shorter hospital stays. Dr. Efthymios Deliargyris noted its game-changing potential, emphasizing the importance of strong clinical evidence for adoption.
CytoSorbents Corporation (NASDAQ: CTSO) announced the appointment of David D. Cox, Ph.D., MBA, as Vice President of Global Regulatory Affairs. Dr. Cox, who previously held a similar role at Integra LifeSciences, has extensive experience in regulatory approvals, including FDA submissions for medical devices. His primary focus will be to expedite U.S. FDA approval for CytoSorb's use in removing ticagrelor during cardiac surgery, a process that has received Breakthrough Device designation. This leadership change is expected to enhance regulatory strategy and facilitate entry into the lucrative U.S. market.
CytoSorbents Corporation (NASDAQ: CTSO) has received approval from the Korean Ministry of Food and Drug Safety for its CytoSorb blood purification technology. This approval allows treatment for various conditions, including cytokine storms, liver disease, and trauma, in a healthcare system serving nearly 52 million people. This marks a significant milestone in expanding CytoSorb's reach, now available in 67 countries. The partnership with Fresenius Medical Care Korea aims to enhance critical care and addresses rising sepsis mortality rates in the region.
CytoSorbents Corporation (NASDAQ: CTSO) has received Health Canada authorization for its CytoSorb® blood purification technology for use in COVID-19 patients. CytoSorb is now commercially available in Canada and has received approvals in 67 countries worldwide. This authorization allows for emergency use in hospitalized COVID-19 patients under Interim Order ID# 316575. The company collaborates with ebbtides medical to expedite availability across Canada as COVID-19 cases rise. CytoSorb is designed to treat inflammation, enhancing outcomes in critical care and cardiac surgery.
CytoSorbents Corporation (NASDAQ: CTSO) has pre-announced record preliminary unaudited financial results for Q4 2020 and full-year 2020, highlighting a significant 73% revenue growth. The company reported approximately $40.8 million in total revenue for 2020, compared to $24.9 million in 2019. Q4 2020 revenue reached about $11.8 million, up from $7.4 million in Q4 2019. CytoSorb treatments exceeded 121,000, reflecting strong demand, especially during the COVID-19 pandemic. The company ended the year with a robust cash balance of over $71 million.
CytoSorbents Corporation (NASDAQ: CTSO) has appointed James Komsa as the new Vice President of U.S. Sales and Marketing. Komsa, a veteran from Medtronic with over 18 years of experience, previously led multiple divisions generating substantial annual sales. He aims to enhance the CytoSorb brand and focus on expanding its critical care applications, particularly for ticagrelor removal in cardiothoracic surgeries. The company is targeting a potential $250 million U.S. market as it leverages FDA Emergency Use Authorization for COVID-19 treatments.
CytoSorbents Corporation (NASDAQ: CTSO) announced that Health Canada has granted Medical Device Authorization for the emergency use and sale of CytoSorb in hospitalized COVID-19 patients. This authorization allows for the therapy's distribution in Canada and expands its reach to 67 countries worldwide. CytoSorbents aims to collaborate with ebbtides medical to ensure rapid availability of the treatment. The authorization is valid until Fall 2021 but may be renewed based on public health needs. CytoSorb has previously received U.S. FDA Emergency Use Authorization.